Abbott Laboratories Pakistan reports higher quarterly profit for the quarter ended September 30, 2026

Financial Result

The board approved financial results for the quarter ended September 30, 2026. Net sales, gross profit, operating profit, net profit and EPS were higher than in the same quarter last year. The quarterly report will be transmitted separately through PUCARS.

Key Findings

  • Quarterly net sales were Rs. 20,629.742 million, compared with Rs. 19,819.134 million a year earlier.
  • Quarterly net profit rose to Rs. 2,543.951 million from Rs. 1,822.546 million; EPS increased to Rs. 25.99 from Rs. 18.62.
  • The September 30, 2026 balance sheet reports cash and cash equivalents of Rs. 10,374.526 million, versus Rs. 13,337.551 million at September 30, 2025.

Financial Performance

MetricPreviousQuarter ended September 30, 2025CurrentQuarter ended September 30, 2026Change
Sales-netPKR 19.82BPKR 20.63B+4.1%
Gross profitPKR 6.73BPKR 7.76B+15.4%
Profit after operating expensesPKR 3.17BPKR 4.22B+32.9%
Net profit for the periodPKR 1.82BPKR 2.54B+39.6%
Basic and diluted earnings per share18.6225.99+39.6%
Finance costsPKR 17.66MPKR 16.15M-8.6%
Cash and cash equivalentsPKR 13.34BPKR 10.37B-22.2%
⚡

Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.

More ABOT announcements

Built for PSX investors

Every filing.Summarised.

Key findings from every PSX announcement, right beside live prices and your portfolio.

Investify company announcements with result figures and filing highlights
Investify announcement summary with key findings from a PSX filing